ClinicalTrials.gg
CompletedNCT02475447Updated Dec 13, 2017

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

A Phase 2 interventional study of Asimadoline and Placebo in Pruritus and Atopic Dermatitis, sponsored by Tioga Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-13.

Sponsored by Tioga Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2017, 9 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
34th of 153
249 · median 70
Started
2015
with 4 others
Phase 2
60 of 163
6 open now
Registered
50th of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 34th largest by enrollment of the 153 interventional ones that give a count, is one of 5 that started in 2015, is one of 60 in phase 2, and was the 50th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the safety, tolerability and clinical efficacy of asimadoline in patients with pruritus associated with atopic dermatitis.

Read the detailed description

Asimadoline has been administered to over 1900 human subjects or patients in clinical trials and exhibits an acceptable safety profile. Due to its high selectivity for the kappa-opioid receptor, asimadoline does not produce mu-opioid like side-effects. Results from preclinical models indicate asimadoline significantly reduces the frequency of scratching induced by pruritic agents. This double-blind placebo-controlled clinical study is designed to evaluate the safety, tolerability and clinical efficacy of asimadoline in patients with pruritus associated with atopic dermatitis.

03

Conditions studied

  • Pruritus
  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Signed and must be able and willing to follow study procedures and instructions
  2. Male or female subject aged 18 years or older (no upper age limit)
  3. Established clinical diagnosis of atopic dermatitis for at least 6 months
  4. Itching Visual Analog Scale (VAS) average worst itching score of at least 40 mm on a 100 mm scale
  5. Female subject of and male subject of procreative capacity agree to use an effective method of for the duration of the study

Main Exclusion Criteria:

  1. Pregnant, attempting to conceive, or nursing
  2. Received phototherapy (ultraviolet B, psoralen plus ultraviolet A) within the previous 4 weeks
  3. Received treatment with any of the following within the previous 2 weeks:

    • Topical or oral or calcineurin inhibitors, sedating anti-histamines or anti-histamines taken for pruritus treatment, prescription topical creams or ointments, any other oral or topical steroids, aprepitant, naltrexone, pregabalin, gabapentin, or tricyclic antidepressants, or any other medications that, in the investigator's judgement, could affect the subject's pruritus or atopic dermatitis, and that are not specified below

    OR taking any of the following and has not been on stable use for at least the previous 4 weeks:

    • Non-prescription topical hydrocortisone creams or ointments, lotions, moisturizers, emollients, bath oil treatments, non-sedating oral anti-histamines being taken for allergy treatment, selective serotonin reuptake inhibitor (SSRI) antidepressants.
  4. Currently participating in other clinical studies or having received investigational drugs in a clinical research study within the previous 3 months. Subjects currently enrolled in an observational study are eligible for participation in this study, however subjects must not enroll in a new observational study during the course of their participation in this study
  5. Pruritus due to conditions other than atopic dermatitis (e.g., hepatitis, biliary cirrhosis, scabies) or due to medications known to cause pruritus
  6. Acute illnesses, uncontrolled or unmanaged diabetes or thyroid disease, decompensated heart failure, cirrhosis or liver failure, chronic kidney disease, or uncontrolled psychiatric disease
  7. Evidence or treatment of (other than localized basal cell cancer, squamous cell skin cancer, or cancer in situ that has been resected) within the previous 5 years
  8. History of infection
  9. History of alcohol or drug abuse within the past 3 years
  10. Diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety and efficacy of the study drug and compliance of the subject with study visits/procedures (e.g. exacerbation of multiple sclerosis or other comorbid conditions)
  11. Use of any product that acts as an inhibitor of P-glycoprotein (P-gp) or as a P-gp substrate (with the exception of topical ketoconazole product for skin or scalp) within the previous 4 weeks
  12. Known allergy to asimadoline or its drug components.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
249 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matched tablets twice daily for 4 weeks.

    Drug: Placebo

  • Experimental
    Asimadoline

    Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.

    Drug: Asimadoline

Interventions

  • kappa-opioid receptor agonist

    Also known as: No brand name, serial number and code name

  • DrugPlacebo

    placebo-matched control

    Also known as: No brand name, serial number and code name

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: Participants will be followed for the duration of the study, an expected 12 weeks

Secondary outcomes

  1. Change from Baseline in Worst Itching Severity using a Visual Analog Scale

    Time frame: 4 weeks

  2. Maximum observed plasma drug concentration (Cmax)

    Time frame: 0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing

  3. Time to reach Cmax in plasma (Tmax)

    Time frame: 0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing

  4. Area under the plasma concentration-versus-time curve (AUC) from the time of the dose to the end of the 12-hour dosing interval

    Time frame: 0.5, 0.75, 1, 1.5, 2, 3, 5, 6 and 8 hours after dosing

07

Study locations

22 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35244, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Axis Clinical Research
    Los Angeles, California 90036, United States
  • Tory Sullivan, MD PA
    North Miami Beach, Florida 33162, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Sneeze, Wheeze and Itch Associates, LLC
    Normal, Illinois 61761, United States
  • Forefront Dermatology
    Carmel, Indiana 46032, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • The Dermatology Group
    Verona, New Jersey 07044, United States
  • Corning Center for Clinical Research
    Corning, New York 14830, United States
  • UNC Dermatology and Skin Cancer Center
    Chapel Hill, North Carolina 27516, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania, Department of Dermatology
    Philadelphia, Pennsylvania 19104, United States
  • Temple Itch Center
    Philadelphia, Pennsylvania 19140, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29621, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • National Allergy and Asthma Research, LLC
    North Charleston, South Carolina 29420, United States
  • Dermatology Treatment and Research Center, PA
    Dallas, Texas 75230, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jun 2017, 23 months.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 23 months is above that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2015
First posted
Jun 18, 2015
StartActual
Jul 2015
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Dec 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02475447
Lead sponsor
Tioga Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 18, 2015
Start date
Jul 2015
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Dec 13, 2017

Study contacts

Dawn McGuire, MD FAAN
study director · Tioga Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asimadoline

Start the discussion